USRE39892EExpiredUtility

Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method

Assignee: DE SIMONE CLAUDIOPriority: Apr 30, 1998Filed: Jul 11, 2006Granted: Oct 23, 2007
Est. expiryApr 30, 2018(expired)· nominal 20-yr term from priority
A61P 31/00A61P 31/08A61P 31/10A61P 31/04A61K 9/0034A61K 35/747A61P 17/00A61P 15/02A61K 9/2054A61K 9/209A61P 15/00A61K 9/0007A61K 39/07
53
PatentIndex Score
0
Cited by
11
References
8
Claims

Abstract

Use of an association of lactobacilli for preparation of a pharmaceutical composition for treatment of vaginosis and vaginitis. Said bacteria association comprises the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species, possibly in combination with one or more species selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus and Lactobacillus gasseri. A pharmaceutical composition comprising said association of lactobacilli adapted for treatment of vaginosis and vaginitis. A method of treating vaginosis and vaginitis based on administration of said pharmaceutical composition.

Claims

exact text as granted — not AI-modified
1. A composition comprising lactobacilli of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species, in the form of pessaries or vaginal tablets comprising at least two layers, both layers containing said species of lactobacilli, in bound form, so that the release velocity of bacteria of the outermost layer is greater than the release velocity of bacteria of the innermost layer. 
     
     
       2. The composition as claimed in  claim 1 , wherein said composition further comprises one or more species of lactobacilli selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus and Lactobacillus gasseri. 
     
     
       3. The composition as claimed in  claim 2 , wherein said lactobacilli consist of the Lactobacillus brevis, Lactobacillus salivarius subs. salicinius and Lactobacillus gasseri species. 
     
     
       4. The composition as claimed in  claim 1 , wherein said lactobacilli are present at a concentration of 10 7  to 10 13  CFU/g. 
     
     
       5. A method of treatment of a vaginal infection, comprising administering through the vagina a composition comprising lactobacilli of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species, in the form of pessaries or vaginal tablets comprising at least two layers, both layers containing said species of lactobacilli, in bound form, so that the release velocity of bacteria of the outermost layer is greater than the release velocity of bacteria of the innermost layer. 
     
     
       6. The method of  claim 5 , said composition further comprises one or more species of lactobacilli selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus and Lactobacillus gasseri. 
     
     
       7. The method of  claim 6 , wherein said lactobacilli consist of the Lactobacillus brevis, Lactobacillus salivarius subs. salicinius and Lactobacillus gasseri species. 
     
     
       8. The method of  claim 5 , wherein said lactobacilli are present at a concentration of 10 7  to 10 13  CFU/g.

Join the waitlist — get patent alerts

Track USRE39892E — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.